As shown in Fig. 1F, the key targets of galangin therapy for HCC, including CCNB1, CDK4, CDK1, and PLK1, belong to the cell cycle signaling pathway (hsa04110). This evidence concerns the gene CDK1 and hepatocellular carcinoma.